Aktuelle Studienübersicht
|
Prostatakarzinom |
|
|
|
|
Nicht interventionell |
|||
| PCO-Studie - Lebensqualität von Prostatakarzinompatienten | weitere Informationen |
||
| adjuvant | |||
| ADAM-Studie: A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy |
aktiv |
|
|
| mHSPC |
|
|
|
|
TALAPRO-3: A Phase 3, Randomized, Double-Blind Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer |
Rekrutierung beendet |
|
|
| ARASAFE - A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with mHSPC |
aktiv |
|
|
|
mCRPC |
|
|
|
|
TriptoSwitch: An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic prostate cancer previously treated and castrated with a GnRH analogue |
aktiv |
|
|
|
Nierenzellkarzinom |
|
|
|
|
adjuvant |
|||
| MK-6482-022: A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy |
aktiv |
|
|
|
nicht-interventionell |
|||
|
AVION: Avelumab + Axitinib als Erstlinientherapie beim lokal fortgeschrittenen und metastasierten RCC |
aktiv |
|
|
|
Urothelkarzinom |
|
|
|
|
nicht muskelinvasiv |
|
|
|
|
MK3475-676: Pembrolizumab + BCG bei persistierendem oder wiederkehrendem Hochrisiko nicht-muskelinvasivem Blasenkarzinom nach BCG-Induktion |
aktiv |
|
|
| muskelinvasiv
|
|
|
|
|
adjuvant |
|
|
|
|
Roche_Imvigor011: A Phase 3, Double-Blind, multicenter, randomised study of Atezolizumab (AntiPD-L1 Antibody) vs. Placebo as adjuvant therapy in Patients with high-risk muscle-invasive Bladder Cancer who are CTDNA positiv folowing cystectomy |
aktiv |
|
|
|
metastasiert / fortgeschritten |
|||
|
AVENUE Studie: Nicht-interventionelle Studie, Chemotherapie mit Gemcitabine / Cisplatin und Avelumab Erhaltungstherapie (Avelumab in real-world treatment of urothelial cancer – The AVENUE NIS) |
aktiv |
|
|